Why Biosimilar Filings Fail: The Complete Technical Guide to 351(k) Rejections, CRL Patterns, and CMC Pitfalls
1. The Stakes: What a Failed 351(k) Filing Actually Costs A Complete Response Letter (CRL) is not an administrative inconvenience. […]
1. The Stakes: What a Failed 351(k) Filing Actually Costs A Complete Response Letter (CRL) is not an administrative inconvenience. […]
1. Why Traditional Drug R&D Is Structurally Broken Between 2000 and 2015, more than 86% of drug candidates that entered
AI in Drug Discovery: The Complete Technical and IP Strategy Guide for Pharma Executives Read Post »
An authorized generic is a brand-name drug sold under a generic label. No new FDA approval required. No new manufacturing
Authorized Generics: The Complete Data Playbook on Prevalence, Timing, and Market Impact Read Post »
The gap between how small-molecule and biologic patents perform at the Patent Trial and Appeal Board has never been wider,
Pharmaceutical pay-for-delay agreements, the precise term is reverse payment patent settlements, sit at the intersection of Hatch-Waxman exclusivity mechanics, branded
Pay-for-Delay Pharma Settlements: The Complete Antitrust & IP Strategy Guide Read Post »
Section 1: What an Authorized Generic Actually Is (And Why Definitions Matter for Deal Modeling) 1.1 The Core Definition An
Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity
DrugPatentWatch reveals NIH funding for patents Read Post »
For IP teams, portfolio managers, R&D leads, and institutional investors who need more than an overview. A pharmaceutical patent is
Pharma Patent Filing Strategies That Maximize Exclusivity: The Complete IP Playbook Read Post »
On NPR’s All Things Considered, Sydney Lupkin asked DrugPatentWatch if drug patents could be used to identify injector pens which
NPR and DrugPatentWatch – Can drug injector pens be swapped? Read Post »
Get fresh news and insights, drug patent expirations & more…